SCHEMBL22816622

SCHEMBL22816622

C1=C(c2ccc(OCc3ccccc3)cc2)CCC2(C1)OCCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGS2 P35354 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PTPN1 P18031 2/20 0.42
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
MAOB P27338 5/20 0.41
MAOA P21397 2/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24460871 0.88 GRIN1 (0.43) GRIN1GRIN2BMAOBMAOABCHE
SCHEMBL5362368 0.84 GRIN1 (0.45) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6269678 0.84 P4HTM (0.40) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL7151373 0.83 GRM2 (0.42) PTPN1GRIN1GRIN2BPRMT5
SCHEMBL24460955 0.81 BRD4 (0.40) MAPTL3MBTL1MCL1
SCHEMBL12208682 0.80 IKBKE (0.41) LMNACYP1A2CYP2C19GAAMAPT
SCHEMBL3140318 0.80 GSTP1 (0.46) GSTP1LMNACYP1A2PTGS1SLC6A2
SCHEMBL31062725 0.80 GRM5 (0.43) SMN1; SMN2PRMT5
SCHEMBL14403246 0.78 TBK1 (0.43)
SCHEMBL19339364 0.78 GRIN1 (0.46) GSTP1LMNACYP1A2PTGS1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT GSTP1 731/4885LMNA 2434/4885CYP1A2 445/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT GSTP1 731/4885LMNA 2434/4885CYP1A2 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.